Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec;5(6):a004630. doi: 10.1101/mcs.a004630

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Dietz et al.; Published by Cold Spring Harbor Laboratory Press

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial License, which permits reuse and redistribution, except for commercial purposes, provided that the original author and source are credited.

PMC Copyright notice

Figure 1. — (A) Schematic of the predicted genomic translocation of KLC1–ALK and aligned ctDNA reads in IGV spanning the rearrangement of KLC1 intron 8 and ALK intron 19. (B) Kinetics of mutated allele frequencies detected in ctDNA during treatment. Corresponding images (I1–I4) are shown in E. Phases of stable disease and progressive disease are indicated on top. (C) Kinetics of serum protein concentrations during treatment. Corresponding images (I1–I4) are shown in D. Phases of stable disease and progressive disease are indicated on top. (D) Corresponding chest CT of the primary tumor (on the left; I1, I3) and brain MRI images of cerebral metastases (on the right; I2, I4) taken during the therapy course. (E) Copy-number profiles of Chromosome 12 from sWGS of ctDNA. The upper panel shows the CNV profile before crizotinib treatment initiation; the bottom panel shows the CNV profile at the end of treatment. (SD) Stable disease, (PD) progressive disease, (CTx) chemotherapy, (RTx) whole-brain radiotherapy.